Charles Schwab’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-80,936
| Closed | -$474K | – | 3340 |
|
|
2019
Q1 | $474K | Buy |
80,936
+17,993
| +29% | +$61.3K | ﹤0.01% | 2781 |
|
|
2018
Q4 | $82K | Hold |
62,943
| – | – | ﹤0.01% | 3105 |
|
|
2018
Q3 | $218K | Buy |
62,943
+8,500
| +16% | +$31.9K | ﹤0.01% | 3065 |
|
|
2018
Q2 | $248K | Sell |
54,443
-100
| -0.2% | -$398 | ﹤0.01% | 3030 |
|
|
2018
Q1 | $180K | Hold |
54,543
| – | – | ﹤0.01% | 3007 |
|
|
2017
Q4 | $213K | Buy |
54,543
+20,400
| +60% | +$111K | ﹤0.01% | 2974 |
|
|
2017
Q3 | $354K | Buy |
34,143
+17,900
| +110% | +$176K | ﹤0.01% | 2819 |
|
|
2017
Q2 | $159K | Hold |
16,243
| – | – | ﹤0.01% | 3062 |
|
|
2017
Q1 | $111K | Hold |
16,243
| – | – | ﹤0.01% | 3004 |
|
|
2016
Q4 | $90K | Hold |
16,243
| – | – | ﹤0.01% | 3049 |
|
|
2016
Q3 | $124K | Hold |
16,243
| – | – | ﹤0.01% | 2994 |
|
|
2016
Q2 | $133K | Hold |
16,243
| – | – | ﹤0.01% | 3030 |
|
|
2016
Q1 | $212K | Hold |
16,243
| – | – | ﹤0.01% | 2884 |
|
|
2015
Q4 | $327K | Hold |
16,243
| – | – | ﹤0.01% | 2833 |
|
|
2015
Q3 | $199K | Hold |
16,243
| – | – | ﹤0.01% | 2959 |
|
|
2015
Q2 | $336K | Buy |
+16,243
| New | +$384K | ﹤0.01% | 2825 |
|
|
2015
Q1 | – | Sell |
-8,200
| Closed | -$253K | – | 3136 |
|
|
2014
Q4 | $253K | Buy |
+8,200
| New | +$228K | ﹤0.01% | 2912 |
|
Charles Schwab's IMDZ Position: Q2 2019 in Review
Charles Schwab sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 80,936 shares — an estimated $474K sold.
Charles Schwab first reported a position in IMDZ in Q4 2014 and held it in 17 quarters. The position peaked at $474K in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Charles Schwab reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Charles Schwab sold 80,936 Immune Design Corp. shares in Q2 2019, an estimated $474K.
- Charles Schwab first reported a position in Immune Design Corp. in Q4 2014 and held it in 17 quarters.
- Charles Schwab's Immune Design Corp. position peaked at $474K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Charles Schwab's 13F filing for Q2 2019, filed 9 Aug 2019.